Griniatsos J, Diamantis E, Gioti J, Karyda I, Vassilopoulos P P, Agnanti N
Saint-Savvas Anticancer Hospital, Athens, Greece.
Anticancer Res. 1998 Jan-Feb;18(1B):683-8.
Recently, using an ultrasensitive time-resolved immuno-fluorometric assay, PSA immunoreactivity (IR-PSA) was found in breast tumor cytosols. We retrospectively studied 219 breast cancer patients, measuring IR-PSA in the tumor cytosols, and classified the breast cancers as either PSA positive or PSA negative based on an IR-PSA cut off level of 1 pg/mg. Multivariated analysis showed that IR-PSA is an independent favourable prognostic indicator for postmenopausal, node positive breast cancer patients. Additionally, IR-PSA correlates with reduced risk of relapse in ER+ve tumors and is negatively correlated with mutated p53, which increases the risk of relapse.
最近，通过超灵敏时间分辨免疫荧光分析法，在乳腺肿瘤细胞溶质中发现了前列腺特异性抗原免疫反应性（IR-PSA）。我们回顾性研究了219例乳腺癌患者，检测了肿瘤细胞溶质中的IR-PSA，并根据1 pg/mg的IR-PSA临界值将乳腺癌分为PSA阳性或PSA阴性。多变量分析表明，IR-PSA是绝经后、淋巴结阳性乳腺癌患者独立的有利预后指标。此外，IR-PSA与雌激素受体阳性（ER+ve）肿瘤复发风险降低相关，且与增加复发风险的p53突变呈负相关。
